Rethinking cancer clinical trials for COVID-19 and beyond

The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential t...

Descripción completa

Detalles Bibliográficos
Autores principales: Doherty, Gary J., Goksu, Mehmet, de Paula, Bruno H. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258610/
https://www.ncbi.nlm.nih.gov/pubmed/35121973
http://dx.doi.org/10.1038/s43018-020-0083-x
_version_ 1783540095820759040
author Doherty, Gary J.
Goksu, Mehmet
de Paula, Bruno H. R.
author_facet Doherty, Gary J.
Goksu, Mehmet
de Paula, Bruno H. R.
author_sort Doherty, Gary J.
collection PubMed
description The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.
format Online
Article
Text
id pubmed-7258610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-72586102020-05-29 Rethinking cancer clinical trials for COVID-19 and beyond Doherty, Gary J. Goksu, Mehmet de Paula, Bruno H. R. Nat Cancer Comment The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care. Nature Publishing Group US 2020-05-29 2020 /pmc/articles/PMC7258610/ /pubmed/35121973 http://dx.doi.org/10.1038/s43018-020-0083-x Text en © Springer Nature America, Inc. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Doherty, Gary J.
Goksu, Mehmet
de Paula, Bruno H. R.
Rethinking cancer clinical trials for COVID-19 and beyond
title Rethinking cancer clinical trials for COVID-19 and beyond
title_full Rethinking cancer clinical trials for COVID-19 and beyond
title_fullStr Rethinking cancer clinical trials for COVID-19 and beyond
title_full_unstemmed Rethinking cancer clinical trials for COVID-19 and beyond
title_short Rethinking cancer clinical trials for COVID-19 and beyond
title_sort rethinking cancer clinical trials for covid-19 and beyond
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258610/
https://www.ncbi.nlm.nih.gov/pubmed/35121973
http://dx.doi.org/10.1038/s43018-020-0083-x
work_keys_str_mv AT dohertygaryj rethinkingcancerclinicaltrialsforcovid19andbeyond
AT goksumehmet rethinkingcancerclinicaltrialsforcovid19andbeyond
AT depaulabrunohr rethinkingcancerclinicaltrialsforcovid19andbeyond

Ejemplares similares